The PATHFINDER study focuses on approximately 20 participants who have endured at least three CDI episodes within the past year. By evaluating the safety and efficacy of ibezapolstat over a 14-day treatment period, Acurx intends to build a clinical foundation for a single, pivotal Phase 3 registration trial. Success in this pilot phase is a critical step toward the company’s goal of securing FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

Executive Chairman Bob DeLuccia noted that the drug could fundamentally alter the treatment landscape by addressing both acute infection and the prevention of recurrence with a single agent. Currently, CDI impacts roughly 500,000 Americans annually, contributing to 30,000 deaths and a massive economic burden. While the company prepares for its international ASPIRE Phase 3 trial, pending sufficient funding, the current PATHFINDER data remains central to ongoing regulatory discussions with the FDA regarding the scope of a future New Drug Application.